Antibodies against 4 Atypical Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis

Patients with rheumatoid arthritis (RA) show autoantibodies against post-translational protein modifications (PTMs), such as anti-citrullinated protein antibodies. However, the range of recognized PTMs is unknown. Here, we addressed four PTMs: chlorination, non-enzymatic glycation, nitration, and ho...

Full description

Bibliographic Details
Main Authors: Lorena Rodríguez-Martínez, Cristina Regueiro, Sámer Amhaz-Escanlar, Carmen Pena, Paloma Herbello-Hermelo, Antonio Moreda-Piñeiro, Javier Rodriguez-Garcia, Antonio Mera-Varela, Eva Pérez-Pampín, Antonio González
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Diagnostics
Subjects:
Online Access:https://www.mdpi.com/2075-4418/12/2/352
Description
Summary:Patients with rheumatoid arthritis (RA) show autoantibodies against post-translational protein modifications (PTMs), such as anti-citrullinated protein antibodies. However, the range of recognized PTMs is unknown. Here, we addressed four PTMs: chlorination, non-enzymatic glycation, nitration, and homocysteinylation, identified as targets of atypical RA autoantibodies in studies whose protocols we have followed. The modified antigens included collagen type II, an extract of synovial proteins and a selection of peptides. We interpreted the results according to the optical density (OD) obtained in an enzyme-linked immunosorbent assay ( ELISA) with the modified antigen and the corrected OD obtained after subtracting the reactivity against the unmodified antigen. The results showed evidence of specific antibodies against glycated collagen type II, as the corrected ODs were higher in the 182 patients with RA than in the 164 healthy controls (<i>p</i> = 0.0003). However, the relevance of these antibodies was doubtful because the magnitude of the specific signal was small (median OD = 0.072 vs. 0.027, respectively). There were no specific antibodies against any of the other three PTMs. Therefore, our results showed that the four PTMs are not inducing a significant autoantibody response in patients with RA. These results indicated that the repertoire of PTM autoantigens in RA is restricted.
ISSN:2075-4418